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ABSTRACT 
As the seventh largest biotechnology cluster, British Columbia is home to 
hundreds of biotechnology companies. These companies have specific legal needs that 
are not currently being served. This business plan contemplates the feasibility of bio.legal 
LLP, a new kind of legal services provider that would offer part time in-house legal 
counsel services to biotech/pharma companies located in British Columbia. 
An analysis of the law firm industry and the current economic state in Canada 
suggests that bio.legal LLP will easily establish itself on the market, aided by fierce 
competition for patent, funding and talent amongst biotech/pharma companies that 
commands that they find innovative ways to improve their competitive advantage. 
bio.legal LLP will assist them in that mission by providing cost effective, flexible and 
specialized legal advice in line with their strategies.  
This feasibility report also proves bio.legal LLP to be an extremely profitable 
venture. 
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1:  OPPORTUNITY  
As an in-house legal counsel in a biotech/pharma company in British Columbia 
with previous experience practising law in a traditional law firm, the author of this 
business report believes that the specific legal needs of biotech/pharma companies are not 
currently being met by existing legal services providers. When these companies require 
legal services, they currently have two choices: contracting out the work to law firms or 
hiring in-house legal counsels.  
1.1 Traditional Law Firms 
For the past 15 years, Canadian law firms have enjoyed continuous growth, 
despite somewhat of a slowdown following the tech bubble burst in 2000 and the 9/11 
events in 2001 (Doucet, 2008). For younger lawyers, the booming economy was not the 
only factor of development; unique opportunities also arose from law firm mergers and 
expansions, increased mobility and an aging workforce (Doucet, 2008).  
In British Columbia, close to 10,000 (3,257 female and 6,547 male) lawyers were 
actively practising law by the end of 2007 (Law Society of British Columbia, 2007). 
Twenty-four percent (24%) of those were practising corporate law, while four percent 
(4%) were involved in other areas such as intellectual property in one of the 3,205 law 
firms established in British Columbia (Law Society of British Columbia, 2007).  
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1.2 In-House Counsel 
Similarly, economic growth of Canadian businesses and an increased focus on 
corporate governance following the Enron scandal have resulted in numerous in-house 
options (Doucet, 2008). The In-House Counsel Barometer, an online survey performed 
by Davies Ward Phillips & Vineberg LLP and the Canadian Corporate Counsel 
Association (“CCCA”) also reveals that significantly more in-house counsels have been 
hired as a cost saving measure since April 2007 (Davies Ward Phillips & Vineberg LLP, 
Canadian Corporate Counsel Association, 2008). The increase in the number of CCCA 
members is an unambiguous indication of the rise of in-house counsels in Canada. In 
2005, the CCCA had 8,400 members (Davies Ward Phillips & Vineberg LLP, 2005) 
while it recorded more than 10,000 members in November 2008 (Canadian Corporate 
Counsel Association).  
1.3 New Business Model: bio.legal LLP 
Due to the limited number of options available and the cost associated with both 
options, biotech/pharma companies will often ignore their legal needs, especially for 
matters that do not appear to influence their bottom lines directly. A company would 
never do a licensing transaction or an initial public offering (IPO) by itself but it will 
compromise the legal value of hundreds of day-to-day contracts. As evidenced by the 
responses to bio.legal LLP’s survey (Appendix 1: Survey To Potential Clients, Appendix 
2: Survey Answers), this is the case for most Biotech/Pharma Companies for which 
executives like Chief Executive Officers, Chief Financial Officers and/or VP’s Corporate 
Development take care of the day-to-day contracts. bio.legal LLP defines “day-to-day 
contracts” as contracts being executed in the ordinary course of business of a company 
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such as Confidentiality and Non-Disclosure Agreements, Clinical Trial Agreements, 
Research Agreements and Consulting Agreements. 
It is put forward that the unmet legal needs of biotech/pharma companies 
constitute an attractive market. This new venture report considers the creation of bio.legal 
LLP, a partnership based on a new business model that would allow Biotech/Pharma 
Companies located in British Columbia, Canada, to access affordable legal services 
relating to their day-to-day operations. “Day-to-day operations” do not only include day-
to-day contracts, but also human resources, immigration and insurance issues. bio.legal 
LLP intends to strengthen its clients’ competitive advantage by providing legal and 
business advice related to day-to-day operations at a fraction of the cost of typical legal 
services providers. bio.legal LLP will add value by: 
 Improving tracking of obligations and financial commitments; 
 Optimizing IP value with adequate protection; 
 Customizing contracts to each situation; 
 Maximizing cash flow through favourable contractual terms; 
 Enhancing vendors’ incentive to complete projects in time; 
 Facilitating access to foreign experts by taking care of immigration 
requirements; and 
 Ensuring compliance with privacy, human rights and labour regulations. 
Besides pricing (as further demonstrated in Section 7.5), bio.legal LLP’s 
competitive advantage lies on its lawyers’ extensive knowledge of the biotech/pharma 
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industry and of the needs of biotech/pharma companies regarding day-to-day operations, 
an expertise unparalleled by existing law firms. bio.legal LLP’s lawyers will work 
directly at their clients’ offices to optimize synergy and favour a collaborative 
relationship with all of their clients’ employees. bio.legal LLP does not intend to replace 
outside law firms for high end/high margin work. Instead, bio.legal LLP offers services 
for which clients are not willing to pay the price charged by large traditional law firms. 
1.4 Positioning and Mission Statements: Optimize your Competitive 
Advantage 
bio.legal LLP’s mission is to optimize its client’s competitive advantage through 
affordable, efficient and specialized legal services. bio.legal LLP is driven by its clients 
and by the market’s needs for safe and effective drugs, medical devices and diagnostic 
tools to supply innovative and outstanding services that will promote its clients’ growth 
and success. bio.legal LLP’s positioning statement has been defined in Table 1 below. 
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POSITIONING STATEMENT 
For small to medium sized Biotech/Pharma Companies located in British Columbia. 
Who require legal advice regarding their day-to-day operations but cannot justify hiring a 
full time in-house counsel or do not find value in paying fees to a traditional law firm for 
day-to-day legal advice.   
bio.legal LLP is a substitute or supplement to outside legal counsel or full-time in-house 
counsel. 
That optimizes its client’s competitive advantage through cost effective, flexible and 
specialized part-time or temporary in-house counsel services in line with the client’s 
strategy. 
Unlike private law firms, bio.legal LLP makes it affordable to receive legal advice 
regarding day-to-day operations that will ultimately contribute to success and growth.  
We have created a new business model to provide legal and business advice to maximize 
enterprise value.  
Table 1. bio.legal LLP's Positioning Statement 
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2:  LAW FIRM INDUSTRY ANALYSIS 
Based on Michael Porter’s Five Forces Analysis (Porter, 1980), the following 
analysis of the law firm industry provides insight to bio.legal LLP regarding the 
challenges faced by law firms in British Columbia, Canada, where bio.legal LLP will first 
enter the market. The most significant forces threatening law firms’ profitability are 
rivalry, supplier power and buyer power. A less critical, but still noteworthy, force 
includes pressures originating from the arrival of new entrants into the industry. Threat of 
substitutes is slowly becoming more menacing for traditional law firms (Figure 1).  
2.1 High Rivalry 
Strong competition within the law firm industry involves many entities of 
different size and scope. Large established firms make it difficult for smaller local firms 
to gain significant market share, especially in the area of commercial law where the large 
established firms are mostly present. The robust growth of the legal industry witnessed 
over the past fifteen years had eased rivalry to a certain extent, but rivalry is expected to 
pick up again due to the instability of the current economy. Law firms practising within 
the same area offer similar products and differentiation across the industry is attained 
through expertise, reputation, location and to a smaller extent, price. Clients can easily 
move from one firm to another with insignificant switching costs. 
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2.2 High Supplier Power 
Law firms have a few important suppliers: information and communication 
technologies, office supplies and landlords. All of these suppliers enjoy strong supplier 
power due to the significant cost to switch supplier and the unlikely possibility of vertical 
or backward integration. These suppliers also have many other customers within and 
outside the law firm industry.  
2.3 Medium Buyer Power 
One would think that with such a large number of players, clients would have the 
bargaining power to negotiate the terms of their relationships with their lawyers. This is 
true to some extent, but the even bigger pool of potential clients weakens their leverage, 
especially with regards to cost. Large brand name institutional clients that law firms fight 
for have a stronger bargaining power, with some of them imposing the rates they want to 
pay. The ability of the sought after institutional clients to change service provider with 
extremely low switching costs makes law firms work hard to retain their valuable 
accounts. Furthermore, these large clients can backward integrate by introducing in-house 
legal services, further increasing the law firms’ pressure to retain their clients. 
2.4 Medium Barriers to Entry 
Brand recognition and the high level of regulatory requirements make the 
entrance of new players arduous, although not impossible. The low capital required to run 
a solo practice makes it easy for any lawyer to start his/her own practice. However, larger 
firms can allocate their large overhead costs over many lawyers, allowing for some sort 
of economies of scale. 
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2.5 Low but Increasing Threat of Substitutes 
In-house corporate counsels have traditionally been the only substitute threatening 
traditional law firms in an industry known for its aversion to innovation and change. The 
increase of in-house counsels over the past years has weakened the law firms’ supremacy.  
Recently, a few firms have entered the market offering legal services under an 
innovative business model that further challenges traditional law firms. This business 
report on bio.legal LLP contemplates this new kind of model.  
In the United States, the most talked about newcomer is Axiom, a law firm with 
220 lawyers on staff and a group of smaller counterparts located across the country 
(Jones, 2008). Axiom offers experienced attorneys available to work on site at a fraction 
of traditional law firms’ rates. Last year, Axiom brought in revenues of $39 million and 
forecasts more than $66 million this year (Jones, 2008). Comparatively, the 100 highest-
grossing law firms in USA grew total gross revenue by 13.6 percent last year to $64.5 
billion (lawyrs, 2008). Despite Axiom’s astonishing success, they are nowhere near 
replacing their more conventional competition, and they believe that their clients will 
continue to use traditional law firms for the vast majority of the legal work that they 
subcontract (Jones, 2008).  
Finally, individual representation is always an alternative, but the complexity of 
most matters handled by law firms makes it an insignificant threat. 
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Barriers to Entry 
 
 Strong brand recognition 
 Strict regulations 
 Low capital required to 
start solo practice 
 Larger firms may have 
economies of scale 
Med 
Threat of Substitutes 
 
 Self representation 
 In-house counsel 
 New legal services 
provider like Axiom 
Low 
Rivalry 
 
 Strong competition 
amongst players of 
different scope and size 
 Presence of large 
established firms 
 Differentiation through 
area of expertise, 
reputation, location and 
price 
 Low switching cost 
 Slowing/decreasing 
market growth 
High 
Supplier Power 
 
 Significant cost to switch 
supplier 
 No likelihood of vertical 
or backward integration 
 Many different customers 
 
High 
Buyer Power 
 
 Credible threat of 
backward integration: in-
house counsel 
 Low switching costs 
 Many clients of different 
scope and size; large 
institutional clients have 
more Buyer Power 
Med 
Figure 1. Law Firm Industry Analysis Based on Michael Porter’s Five Forces Analysis 
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2.6 National and Economic Trends 
Recent turmoil in the world economy has led to much speculation regarding 
Canada’s economic health. On November 11th, 2008, Mr. Dale Orr, a managing director 
of Global Insight said the country will lose 100,000 jobs in the first three months of 2009 
and believes Canada has already entered its first recession in 17 years (Beltrame, 2008). 
In parallel, the Bank of Montreal declared that Canada’s resource-sector boom that 
sustained much of the country’s growth the past few years has ended after commodity 
prices plummeted another 16.7 per cent in October, the largest one-month decline in the 
index’s history since January 1965 (Cooper, 2008). These projections and data are just a 
few examples of current market uncertainties. It is expected that corporations will attempt 
to reduce their cash burn rate and take different measures to recession-proof their 
businesses until the actual extent of the crisis is known.  
Usual consequences of recessions such as lower gross domestic product, a higher 
unemployment rate, and higher government deficits understandably affect Canadian 
businesses, especially in sectors such as manufacturing, and result in less work for both 
internal and external lawyers (Doucet, 2008). As a result, rivalry will increase and so will 
buyer power. Depending on the size and length of the anticipated recession, traditional 
law firms may try different strategies to differentiate themselves and retain the business 
of their larger clients. New entrants like bio.legal LLP could suffer from those strategies. 
  
  
 11 
3:  HOW WILL THE FORCES AFFECT BIO.LEGAL LLP AS 
A NEW ENTRANT? 
bio.legal LLP believes that the threatening forces present in the law firm industry 
will not impact it in the same way they affect traditional law firms.  
3.1 Medium Threat of Substitute 
bio.legal LLP will obviously compete against traditional law firms and in-house 
legal counsels but, because of its speciality and target market, bio.legal LLP considers 
traditional law firms and in-house legal counsels as being substitutes rather than direct 
competitors. Direct competitors will be newcomers like Axiom and Cognition LLP. 
bio.legal LLP does not believe that these competitors will be the most harmful ones. 
Instead, bio.legal LLP expects that its biggest competitors will be the CEO’s, CFO’s or 
any other non-lawyer employees that take care of the day-to-day contracts in most 
Biotech/Pharma Companies. In other words, bio.legal LLP’s primary substitute is the 
ignorance of one’s legal needs regarding the day-to-day contracts.  
3.1.1 Traditional Law Firms with Expertise in Biotechnology or Life Sciences 
In order to be considered as a potential competitor of bio.legal LLP, a law firm 
must offer services in the areas of life sciences and/or biotechnology. In British 
Columbia, it appears that only five law firms offer services in such areas; Farris Vaughan 
Wills & Murphy, Fasken Martineau, McCarthy Tétrault, Gowlings and Lang Michener.  
All of these law firms are large established firms that are fighting for the high end/high 
  
 12 
margin transactions with little interest or expertise regarding the less glamorous day-to-
day contracts. In fact, only one Canadian national firm promotes its services for the day-
to-day contracts of biotech companies, supporting bio.legal LLP’s belief that those needs 
are not currently being addressed.  
According to bio.legal LLP’s survey (Appendix 2: Survey Answers), law firms 
are appreciated for their prompt services, their breath of experience in the client’s field, 
their expertise and their comprehensive level of services. Law firms’ most important 
disadvantage is their costs. As one respondent describes it, “[Law firms’] fees are 
excessive and based on a strategy to maximize fees not for the ultimate long term benefit 
of the company” (Appendix 2: Survey Answers). 
3.1.2 In-House Counsels in Biotech/Pharma Companies 
A generalisation of the answers to bio.legal LLP’s survey (Appendix 2: Survey 
Answers) would suggest that none of the Biotech/Pharma Companies in British Columbia 
has an in-house legal department. Although it has been impossible to obtain the actual 
number of in-house counsels currently employed by Biotech/Pharma Companies, 
bio.legal LLP dismissed such suggestion and rather estimated that less than 10% of them 
have an in-house legal department. Known companies that currently have a legal 
department include QLT, Angiotech and Cardiome Pharma Corp.  
In-house counsels are generally hired on a full time basis without any possible 
adjustment to demand. This inflexibility contributes to a general belief that in-house 
counsels are too expensive (see Appendix 2: Survey Answers). 
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The threat of substitution from full time in-house counsels may increase overtime 
as bio.legal LLP’s clients witness the benefits of in-house counsel and grow to a point 
where they need full-time services. 
3.1.3 Real Competition: Ignorance of Legal Needs 
It can be deduced from the responses to bio.legal LLP’s survey (Appendix 2: 
Survey Answers) that most Biotech/Pharma Companies do not find value in paying fees 
to traditional law firms or in supporting the costs of an in-house legal department for day-
to-day legal advice. Instead, their senior executives negotiate their day-to-day contracts. 
bio.legal LLP believes that these companies are honestly convinced that they are 
appropriately handling their day-to-day operations from a legal point of view. Aside from 
the fact that the executives taking care of these day-to-day contracts do not have a legal 
background, the concern is that the same templates are repeatedly being used without 
making any adjustments to address the specificities of each situation. Furthermore, 
executives have many other obligations, which prevent them from giving sufficient 
attention to contracts, leaving their firm exposed without appropriate recourses if the 
contractual relationship turns sour. It is bio.legal LLP’s belief that these companies are 
adversely affecting their competitive advantage by neglecting their legal needs and that 
they realize often too late that they should have had proper legal advice. 
3.2 Low Rivalry: Axiom, Cognition LLP and Other Legal Services 
Providers Based on the Same Business Model 
Given Axiom’s tremendous success in the USA, bio.legal LLP expects that many 
law firms will emerge under the same business model. In Canada, the only comparable 
entity is Cognition LLP, an Ontario law firm established in 2005 that offers services 
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similar to those provided by Axiom and contemplated by bio.legal LLP. Both of these 
newcomers offer in-house counsel services to companies as an alternative to full time in-
house counsel or as a supplement to existing legal department when demand is too high. 
These new competitors do not currently pose a serious threat to bio.legal LLP as there is 
no known legal services provider offering this type of services in British Columbia or for 
the biotech/pharma industry.  
3.3 Medium Barriers to Entry 
The extremely low start-up costs combined with the high return on investment are 
two attractive incentives for potential newcomers. However, new entrants will probably 
not target the biotech/pharma companies like bio.legal LLP because of the high level of 
expertise required to give legal advice to these companies and because of the small size 
of the market.  
3.4 Medium Buyer Power 
With its capacity being less than the expected demand (as further explained in 
Section 5.35:  ), bio.legal LLP’s will be available to a limited number of clients, an 
exclusivity that will reduce buyer power to a low threat.  
3.5 Low Supplier Power 
bio.legal LLP will not rent class A office space or use highly sophisticated or 
customized systems to track its time or to store its electronic documents. This should 
significantly reduce switching costs, thereby weakening supplier power.  
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3.6 Current Economic Trends 
bio.legal LLP forecasts that the economic meltdown will encourage businesses to 
find ways to reduce spending while remaining competitive. This mindset should facilitate 
bio.legal LLP’s entrance on the market and contribute to the adoption of its services. 
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4:  BIO.LEGAL LLP’S CUSTOMERS 
4.1 The Pharmaceuticals, Biotechnology and Life Sciences Industry in 
British Columbia, Canada 
According to the Organisation for Economic Co-Operation and Development 
(OECD), biotechnology can be defined as "the application of scientific and engineering 
principles to the processing of materials by biological agents to provide goods and 
services” (OECD, 2005). The biotechnology industry includes organizations active in the 
areas of biopharmaceuticals, medical devices, bio-products, bioinformatics, 
nanotechnology, agriculture, marine, environmental and forestry.  
In British Columbia, biopharmaceuticals account for the largest portion of the 
biotechnology industry. In 2005, the biopharmaceuticals sector was composed of roughly 
91 companies with annual revenues of approximately $779 million according to a 2005 
Statistics Canada report (Ministry of Economic Development, British Columbia). In 
contrast, the BC Medical Device Technologies Association (BC MedTech) reported 63 
member companies directly involved with medical devices (Ministry of Economic 
Development, British Columbia).  
British Columbia has been identified as the fastest growing biotech centre in 
Canada and as the seventh (7
th
) largest biotech cluster in North America (Life Sciences 
British Columbia, 2007).  
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4.2 Biotech/Pharma Industry Analysis 
The biotech/pharma industry has been analysed using Porter’s Five Forces 
Analysis (Porter, 1980) and has been assessed as highly competitive (Figure 2). Rivalry, 
supplier power and buyer power are threatening firms’ ability to become and remain 
profitable. Younger firms are also greatly affected by the numerous barriers to entry, 
which have effect until the company is financially self-sufficient with its first product on 
the market. Substitutes are only moderately influencing biotech/pharma companies’ 
profitability. 
4.2.1 High Rivalry 
Rivalry is the strongest force threatening biotech/pharma companies. Many firms 
of different scope and size are competing for patent protection and for the support of 
doctors prescribing their product. The low switching costs for buyers increases rivalry. 
The fact that the firms can differentiate their products almost indefinitely and that more 
than one treatment can exist on the market for the same indication slightly eases rivalry.  
4.2.2 High Buyer Power 
Buyer power becomes a threat to biotech/pharma companies only when they have 
products on the market. Although it takes many years to bring a product to market, young 
biotech/pharma companies should not ignore this force. If a drug cannot provide an 
acceptable return on investment, a company should not invest time and money in 
pursuing its development. This reality needs to be continually reconsidered as more 
information is obtained on the efficacy, safety and the anticipated Cost of Good Solds of 
the product to ensure that no resources are wasted. The major buyers of prescription 
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drugs vary from one country to another. In Canada, prices are set by regulation, which 
translate into a strong buyer power for the government health authorities. Buyer power is 
weakened when individuals or smaller organizations purchase the product. Generally, 
individual buyers have low switching costs for over-the-counter drugs except when there 
is only one treatment available. For prescribed drugs, the ultimate decision maker is the 
prescribing doctor. In that case, the buyer power of individuals will remain strong only if 
generics are available on the market.  
4.2.3 High Supplier Power 
Suppliers of biotech/pharma companies include suppliers of raw materials, contract 
manufacturing organizations, contract research organization and suppliers of 
administrative services. The biotech/pharma industry has been faced with a constant 
increase of the price of raw materials over the past several years. Biotech/pharma 
companies are particularly vulnerable to price increases for critical raw materials that 
cannot be purchased elsewhere. Changing of suppliers of raw materials and contract 
manufacturing organizations is done at very high switching costs; tech transfer can take 
more than a year and the regulatory process required to certify a new organization is also 
lengthy. Long established suppliers are now facing mounting competition from Chinese 
and Indian suppliers, creating a rivalry that could ultimately benefit biotech/pharma 
companies if these new suppliers are able to comply with western quality standards 
despite weak local regulations and if it results in a reduction of the price of raw materials. 
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4.2.4 High Barriers to Entry  
Many barriers to entry exist in the biotech/pharma industry. Ten years ago, it took 
on average 14.8 years and around $250 million to bring one drug to market in the USA 
(Harvard School of Business, 1998). This lengthy and expensive process combined with 
the hefty regulations creates strong barriers to entry. In addition, firms compete 
aggressively for financing and for patent protection. Potential sky rocketing return on 
investment, the low switching costs of buyers and the low brand recognition are 
components that attract newcomers in the biotech/pharma industry. 
4.2.5 Low Threat of Substitutes 
The threat of substitutes is weak for the biotech/pharma industry. Patent and other 
types of intellectual property delay the apparition of cheaper substitutes, allowing the 
firms to enjoy a monopoly position for a certain number of years. It is only upon 
expiration of the patent protection that generics are legally allowed on the market. Even 
then, biogenerics are extremely difficult to imitate, further reducing the threat for 
biotechnology companies. Biotech/pharma companies also see the holistic medicines as a 
substitute, mainly for over-the-counter products (Pharmaceuticals, Biotechnology & Life 
Sciences Industry Profile: Global, 2008).  
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Figure 2. Biotech/Pharma Industry Analysis Using Michael Porter’s Five Forces Analysis 
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4.3 bio.legal LLP’s Target Market 
4.3.1 Fit with bio.legal LLP’s Expertise 
In selecting its market, bio.legal LLP has excluded certain categories of 
biotechnology companies, as they do not operate in bio.legal LLP’s scope of expertise. 
This is the case for companies doing business in the areas of bio-products, environment 
and forestry for example. Companies that are providing services to biotech/pharma 
companies such as laboratories were also excluded due to potential conflicts of interest. 
Non-profit and governmental institutions have also been excluded from the list of 
potential clients because of their particular corporate structure. Finally, companies that 
are headquartered outside of British Columbia or large multinational companies have 
been excluded. 
As a result of the above mentioned exclusions, it has been decided that bio.legal 
LLP’s should concentrate its services around small to medium-sized companies that are 
involved in the areas of biopharmaceuticals, medical devices and diagnostics located in 
British Columbia (hereinafter, the “Biotech/Pharma Companies”). The Biotech/Pharma 
Companies are particularly vulnerable to the forces described in Section 4.2 above and 
bio.legal LLP believes that a stronger competitive advantage would dampen the adverse 
effects of the forces. bio.legal LLP has put together a list of all known Biotech/Pharma 
Companies, for a total of 53 potential clients, and sent them a survey to gather more 
information about their needs regarding legal services (see Appendix 1: Survey To 
Potential Clients and Appendix 3: List of Biotech/Pharma Companies).  
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4.3.2 When Does a Company Need an In-House Counsel? 
According to Mr. Stephen E. Seckler of General Counsel Consulting (Seckler, 
2007), some factors directly influence the need for hiring a full-time or part-time lawyer: 
 Sales exceed $10 million and/or the headcount of the company goes beyond 250; 
 The company provides a service or sells a product that has the potential to cause 
great physical, emotional, or financial harm; 
 The company owns and/or leases several properties; 
 The company deals with a high volume of contracts with vendors and clients; 
 The company is in a regulated industry; 
 The business is heavily involved in the purchase, sale, and/or development of 
valuable intellectual property; 
 The company is contemplating going public; and 
 The company is facing a serious legal/PR problem that is likely to linger. 
Ms. Sandra L. Etherton of Etherton Law Group, LLC seems to agree with Mr. 
Seckler, identifying the major factors as the amount of revenue, the number of 
employees, the company’s plans to go public and the nature of its industry with respect to 
intellectual property (Etherton, 2001). However, Ms. Etherton downplays the importance 
of the revenue factor and replaces it with the cash burn rate for companies that do not 
have revenues yet, like most Biotech/Pharma Companies. According to Ms. Etherton, 
when a company with no revenue spends $25-$30 million annually, it should consider 
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having in-house counsel, even more so when the company is publicly traded or plans an 
initial public offering (Etherton, 2001). 
As further explained, small to medium sized Biotech/Pharma Companies meet 
almost all the factors described above, supporting bio.legal LLP’s assertion that bio.legal 
LLP’s services are required.  
4.3.3 The Special Needs of Biotech/Pharma Companies 
Drug development costs many millions of dollars and takes many years to 
complete. It is also highly competitive with many companies competing for patients, 
funding and qualified staff. In order to maintain competitive advantages over much 
larger, international pharmaceutical companies, Biotech/Pharma Companies need to 
ensure that their efforts are focused and their funds spent wisely. 
Early on in the research and development process, it is essential that 
Biotech/Pharma Companies proactively protect any confidential information that is being 
disclosed and retain all rights to the intellectual property developed with such 
confidential information. Unfortunately, without an in-house legal counsel, 
Biotech/Pharma Companies often use standard templates that do not adequately protect 
the company’s information and intellectual property, thereby jeopardizing any advantage 
against competitors and weakening licensing ability.  
Furthermore, most small to medium sized Biotech/Pharma Companies do not 
have the physical resources to develop a product entirely in-house. Instead, they 
outsource a lot of the work to vendors commonly referred to as Clinical Research 
Organizations and Clinical Manufacturing Organizations. Biotech/Pharma Companies 
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also draw upon the expertise of key opinion leaders and other consultants. All such 
activities must be controlled and managed with appropriate contracts, which can number 
up to several hundred contracts per year. All of these day-to-day contracts must be 
carefully crafted to ensure that they will be enforceable against delinquent vendors. 
Finally, as most Biotech/Pharma Companies need outside funding to support their 
development process, most become subject to regulations applicable to public companies. 
As a result, companies must establish internal rules and processes that comply with U.S. 
Sarbanes-Oxley rules and relevant Canadian rules as early as possible. Additionally, 
companies need to anticipate that they will be accountable to shareholders, venture 
capitalists, securities and other governmental authorities. Biotech/Pharma Companies 
publicly traded in the US should also be particularly cautious of the litigious culture in 
the US market.  
Although all the respondents of bio.legal LLP’s survey have answered that day-
to-day contracts are very important for the success of the company, only one of them use 
qualified lawyers to negotiate those contracts (Appendix 2: Survey Answers). This is 
even more surprising when taking into account the fact that those respondents spend 
between $50,000 and $12 million annually on external vendors, with an average of $2.3 
million per year (Appendix 2: Survey Answers). 
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5:  SALES FORECAST 
5.1 Demand Estimation for bio.legal LLP’s Services 
Through its online survey, bio.legal LLP asked potential clients to estimate their 
needs for bio.legal LLP’s services (see responses in Appendix 2: Survey Answers). Based 
upon these numbers, bio.legal LLP calculated the averaged hourly need per 
Biotech/Pharma Company. bio.legal LLP then applied the averaged hourly need to the 
different estimates regarding the size of the biotech/pharma industry in British Columbia. 
As demonstrated in Table 2. Demand Estimates for bio.legal LLP's Services, demand 
from the biotech/pharma industry (including medical devices and diagnostics) could be 
considerable. However, it is important to note that bio.legal LLP’s estimates may not be 
statistically valid given the survey’s low response rate (~10%). All assumptions and 
further explanations of methodology are provided in Appendix 4: Demand Estimates 
Assumptions.  
  
 26 
 
Table 2. Demand Estimates for bio.legal LLP's Services 
5.2 Underlying Assumptions of Sales Forecast 
According to the above-mentioned demand estimates, bio.legal LLP could reach 
annual sales of $3.5 million in its first few years of existence. As good as this sounds, the 
demand estimates was not used to develop the sales forecasts of bio.legal LLP. This is 
due to bio.legal LLP’s limited capacity to provide services with only two partners on 
hand. This business plan cannot assume that bio.legal LLP will be able to take on enough 
partners or hire enough employees or independent contractors to accommodate demand 
because of the specialization required to provide quality services to the targeted audience. 
Estimated number of 
companies
Days per month
Hours per 
month
Monthly Revenues
% of monthly 
capacity
Annual Revenues
154 205 1643 287,467$               540% 3,449,600$             
90 120 960 168,000$               316% 2,016,000$             
53 71 565 98,933$                 186% 1,187,200$             
Estimated number of 
companies
Days per month
Hours per 
month
Monthly Revenues
% of monthly 
capacity
Annual Revenues
116 154 1232 215,600$               405% 2,587,200$             
68 90 720 126,000$               237% 1,512,000$             
40 53 424 74,200$                 139% 890,400$                
Estimated number of 
companies
Days per month
Hours per 
month
Monthly Revenues
% of monthly 
capacity
Annual Revenues
77 103 821 143,733$               270% 1,724,800$             
45 60 480 84,000$                 158% 1,008,000$             
26.5 35 283 49,467$                 93% 593,600$                
Estimated number of 
companies
Days per month
Hours per 
month
Monthly Revenues
% of monthly 
capacity
Annual Revenues
39 51 411 71,867$                 135% 862,400$                
23 30 240 42,000$                 79% 504,000$                
7 9 71 12,367$                 23% 148,400$                
If, on average, 100% of the companies require 1.33 day per month
If, on average, 50% of the companies require 1.33 day per month
If, on average, 25% of the companies require 1.33 day per month
If, on average, 75% of the companies require 1.33 day per month
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Growth alternatives include training lawyers or diversifying bio.legal LLP’s targeted 
clients.  
In addition, each client is different and it has been impossible to single out one 
factor that directly influences the number of hours required by a client. As such, it 
impossible to determine whether the monthly average number of hours required obtained 
with the survey is statistically representative or not. 
All other assumptions that were used to arrive at the sales forecast have been 
explained in full in Appendix 5: Sales Forecast Assumptions.  
5.3 bio.legal LLP’s Capacity 
This business report contemplates the viability of bio.legal LLP, a limited liability 
partnership composed of only two partners. If both partners provide services on a full 
time basis (assuming 8 hours per day) from Monday to Friday, with no time allocated to 
marketing, general administration, vacation or sick days and professional development, 
the maximum capacity of bio.legal LLP would be 4,032 hours per year. With nine days 
per partner allocated annually to continuing legal education (see Appendix 6: Calendar of 
Professional Development) and 15 days per partner for vacation, the maximum capacity 
of bio.legal LLP would decrease to 3,648 hours per year (228 days) based on bio.legal 
LLP’s actual working days in 2009 (Appendix 7: bio.legal LLP’s Working Days in 
2009). From this amount, enough time needs to be subtracted to allow for general 
business administration and marketing. It has been estimated that bio.legal LLP’s 
partners should not work more than 80% of the maximum capacity, resulting in a final 
capacity of 2,918 hours or 1,459 hours per partner.  
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5.4 Projected Sales 
Projected sales of bio.legal LLP’s services will continue to grow into the year 
2011. At that point, bio.legal LLP’s partners will work on billable hours 80% of the 
working days. They will use the other 20% for marketing and general administrative 
tasks. 
Projected sales of bio.legal LLP’s services 
will reach the maximum level by bio.legal LLP’s 
third year of activity, providing that bio.legal LLP 
does not take on more partners or hire employees 
or independent contractors. Based on the demand 
estimates for bio.legal LLP’s services and on 
Cognition LLP’s experience (Milstone, 2008), it is 
very well possible that bio.legal LLP will reach its 
maximum capacity by the end of its first year. 
Figure 3. bio.legal LLP's First Year Sales Forecast 
displays the predicted sales for the first year of 
bio.legal LLP while Figure 4. bio.legal LLP's 
Three Year Sales Forecast shows the projected sales over the first three years of activity 
of bio.legal LLP. 
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6:  SHOULD BIO.LEGAL LLP ENTER THE MARKET?  
For a quick answer, yes, bio.legal LLP should enter into the market. This 
feasibility report clearly demonstrates that the forces threatening traditional law firms 
would not affect bio.legal LLP as much, suggesting that bio.legal LLP should be able to 
enter into the market without major obstacles. As the seventh largest biotechnology 
cluster, British Columbia is an ideal location for bio.legal LLP and feedback from the 
industry clearly suggests that there are unambiguous needs for bio.legal LLP’s services.  
Demand is expected to rapidly exceed bio.legal LLP’s capacity, suggesting that 
bio.legal LLP’s will be extremely profitable with many opportunities for growth and 
expansion.   
The following sections will discuss bio.legal LLP’s implementation plan.  
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7:  MARKETING PLAN 
7.1 bio.legal LLP’s Services 
bio.legal LLP’s services have been designed to help Biotech/Pharma Companies 
overcome the threatening forces described in Section 4.2 above by optimizing their 
competitive advantage. They are described below in order of interest evidenced by the 
answers to bio.legal LLP’s survey (Appendix 2: Survey Answers). 
7.1.1 Part-time or Project Base Services 
If hired part-time, bio.legal LLP will go to the office of its client according to a 
schedule determined in advance. bio.legal LLP’s lawyers would preferably attend their 
clients’ offices weekly or bi-weekly in 
order to maximize their impact. bio.legal 
LLP will oversee the day-to-day 
operations of its clients described in Table 
3, as requested by each client.  
If hired on a project base, bio.legal 
LLP will be involved in a limited number 
of matters, a large worldwide clinical trial 
for example. In that case, bio.legal LLP 
will also work from its client’s office, but 
for a limited period only. 
Part-Time Services include: 
 
 Meeting with team requesting the 
contract 
 Drafting, reviewing and negotiating 
contracts 
 Advising companies on: 
- Human rights issues 
- Labour issues 
- Immigration issues 
- Corporate governance 
- Management of IP portfolio 
- Insurance 
 Conflict resolution 
 Management of external counsel 
 Drafting templates 
 Training employees 
Table 3. Description of bio.legal LLP’s Part-
Time Services 
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7.1.2 Training Sessions 
bio.legal LLP will offer training sessions to its clients’ employees. Topics will 
vary according to the clients’ needs, but all the training sessions will be offered based on 
the package described in Table 4. Potential topics include insider trading, corporate 
governance, confidentiality obligations, etc. 
The cost of these sessions will be 
significantly less than what a client would 
pay if bio.legal LLP was charging its hourly 
rate and pass-through expenses for the 
materials. This discount is offered because 
bio.legal LLP considers that the training 
sessions are a good marketing tool and will ultimately attract more business for bio.legal 
LLP. 
7.1.3 Setting Up Interactive Database for Contracts 
An interactive database is a precious tool for contract management. It allows 
employees to access all the documents 
posted on the database while controlling 
who has access to which documents. 
Accounting can review the payment 
terms before processing an invoice, 
while others can keep track of the 
timelines in each contract. The 
Included in the Training Session 
Package: 
 
 Initial meeting with senior 
management 
 Preparation of PPT presentation 
 One-hour long presentation 
 Hand out of supporting materials 
 Answer to follow-up questions 
Included in the Interactive Database 
Package: 
 
 Initial meeting with senior management 
 Meetings with key stakeholders 
 Meetings with potential service providers 
 Customization of database selected 
 Training of client’s employees 
Table 4. Description of the Services Included 
in bio.legal LLP's Training Session Package 
Table 5. Description of the Services Included in 
bio.legal LLP's Interactive Database Package 
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interactive database is also very useful to request comments and keep track of the 
different versions of a contract.  
If bio.legal LLP is hired to set-up an interactive database, it will take care of all 
the necessary steps as described in Table 5, making this change painless for the client and 
its employees. 
7.1.4 Setting Up Legal Department 
If bio.legal LLP’s clients have enough business to justify hiring a lawyer or a 
paralegal, bio.legal LLP will help such clients establish their legal department. In this 
case, the scope of the project will 
depend on the qualification and 
experience of the selected candidate(s), 
including some or all the elements 
described in Table 6. This service will 
only make sense if bio.legal LLP will 
retain or gain some business from such 
clients or for long standing clients of 
bio.legal LLP. 
7.2 Sales Strategy 
bio.legal LLP will attempt to recruit new clients while solidifying its relationships 
with existing clients. Potential clients initially targeted will be those that are about to 
initiate a large clinical trial, those that have just or will soon receive marketing approval 
and those that have just became or will soon become publicly traded. These types of 
Included in the Legal Department 
Package: 
 
 Initial meeting with senior management 
 Meetings with key stakeholders 
 Co-ordination with head hunters 
 Screening of candidates 
 Establishment of policies and processes 
 Draft of standard templates 
 Training of selected candidates 
Table 6. Description of the Services Included in 
bio.legal LLP's Legal Department Package 
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milestones have been identified as events that directly influence the need for legal advice 
concerning day-to-day operations and bio.legal LLP expects that these companies will 
likely see value in having in-house legal services. bio.legal LLP’s push to increase its 
market share will be aided by the current economic downturn, which will force 
companies to look for cost effective alternatives in order to conserve cash. bio.legal LLP 
will also focus on its area of expertise, its flexibility and its supplementary role as 
business advisor. bio.legal LLP’s sales strategy will be to convince a biotech company to 
hire bio.legal LLP for a small project in order to demonstrate how valuable in-house legal 
services are. bio.legal LLP hopes that once the clients will have had a glimpse at what 
bio.legal LLP can offer, they will want more. bio.legal LLP expects that scepticism, 
complacency and ignorance will be its biggest hurdles in securing work from clients. 
bio.legal LLP plans to overcome these obstacles by providing education to its potential 
and existing clients. In summary, our marketing goals are as follows: 
1. Educate Biotech/Pharma Companies and create awareness about the value of in-
house legal counsel; 
2. Create brand recognition about bio.legal LLP; and 
3. Deliver consistently good services, take initiatives and fulfil commitments in a 
timely manner to ensure retention. 
7.3 Promotion of bio.legal LLP’s Services 
7.3.1 Life Sciences British Columbia 
Life Sciences British Columbia (“Life Sciences BC”) “represents and supports 
British Columbia’s life sciences and biotechnology industry and wider community 
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through advocacy, facilitation of economic development and promotion of [the] industry 
locally, nationally and internationally” (Life Sciences British Columbia, 2007). In a 
sense, Life Sciences BC is a central forum for BC’s biotechnology cluster. As such, it is 
the best medium to advertise bio.legal LLP’s services. bio.legal LLP will put an 
advertisement in the magazine Life Sciences British Columbia 2009, official publication, 
published by BIV magazines and which will be distributed in March 2009 to 5,000 
people.   
A link to bio.legal LLP’s website will also be posted on the website of Life 
Sciences BC. This opportunity comes at no cost to bio.legal LLP as it is a free service 
offered to all the members of Life Sciences BC.  
Life Sciences BC also organizes numerous networking events. Those events take 
place many times year-round and participation is offered at a minimal cost. Those events 
will be perfect to connect with potential clients and to create awareness about the services 
of bio.legal LLP. 
7.3.2 Meeting with Potential Clients 
According to Mr. Joe Milestone, one of the founding partners of Cognition LLP, 
having five minutes of someone’s time is often sufficient to secure a meeting with the 
management team (Milstone, 2008). Ms. Sage Baker, the former Vice President of Global 
Corporate & Investor Relations for Aspreva Pharmaceuticals and a seasoned consultant 
currently working for FD International in San Francisco, suggests meeting with 
executives with a clear plan that addresses existing needs (Baker, 2008). For the 
transcripts of the interviews with Mr. Joe Milestone and Ms. Sage Baker, see Appendix 
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8: Transcript of Interview with Mr. Joe Milestone of Cognition LLP and Appendix 9: 
Transcript of Interview with Sage Baker of FD International, respectively.  
bio.legal LLP intends to follow the above advice and to meet potential clients 
directly to offer a more comprehensive description of its services. bio.legal LLP will 
make a Power Point presentation to senior management and/or the board of directors to 
clearly explain how its services will add value to their bottom line. Before its meeting 
with a particular potential client, bio.legal LLP will gather as much information as 
possible about the company’s pathway, goals and strategy and will possibly meet with 
one or two key executives beforehand to discuss the client’s needs. Each presentation will 
be personalized in accordance with bio.legal LLP’s findings. 
7.3.3 Website: www.biolegal.com 
In December 2008, a website will be designed to explain bio.legal LLP’s concept, 
describe its services and provide the biographies of Emmanuelle Vallée and Jennifer 
Begg. As bio.legal LLP develops long-term relationships with clients, statements of 
appreciation and case studies will be posted on the website to enforce a “word-of-mouth” 
effect. The website will be hosted at www.biolegal.com, a domain name currently 
available for sale. As it is unlikely that clients will search for a company like bio.legal 
LLP, bio.legal LLP will not rely on its website as the first point of contact with new 
customers. However, bio.legal LLP believes that potential clients who have met 
Emmanuelle Vallée or Jennifer Begg will appreciate having a chance to gather more 
information about the company and to verify their credentials before a follow-up 
meeting.  
  
 36 
7.3.4 Conferences and Tradeshows 
As a mandatory requirement established by the Law Society of British Columbia, 
Emmanuelle Vallée and Jennifer Begg will attend continuing legal development 
conferences offered to in-house counsel. bio.legal LLP will benefit from these 
conferences by taking the opportunity to market its services to in-house counsel already 
working in biopharmaceutical companies located in British Columbia. In these cases, 
bio.legal LLP will put emphasis on its supplementary services offered to companies that 
already have an in-house legal department. Instead of seeing these existing in-house 
counsels as competitors, bio.legal LLP will treat them as potential collaborators from 
whom they could get business to cover during a maternity or sick leave or just to offer 
supplementary services in times of necessity.  
7.4 Strategic Alliances with Traditional Law Firms 
As previously mentioned, large traditional law firms should not feel threatened by 
bio.legal LLP’s services. bio.legal LLP offers services for which clients are not willing to 
pay the price charged by outside counsels. Instead of competing with these law firms, 
bio.legal LLP will attempt to develop mutually beneficial relationships with at least one 
of the five law firms in British Columbia that has expertise in the biotech/pharma 
industry. When these law firms have a client that requires services regarding its day-to-
day operations, the law firm would refer them to bio.legal LLP. In exchange, bio.legal 
LLP would undertake to suggest the law firm’s services whenever bio.legal LLP’s clients 
are dealing with a matter that requires expertise that bio.legal LLP cannot offer.  
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7.5 Pricing 
7.5.1 Pricing Strategy 
bio.legal LLP will offer its services at a competitive price point, but penetration 
pricing will not be employed to undercut bio.legal LLP’s competition. The pricing 
strategy will be consistent with the objective of the firm which is to develop bio.legal 
LLP’s brand image as one of quality and professionalism. Price discounts and premiums 
might possibly be assigned to clients according to clients’ needs and types of 
commitment.  
7.5.2 Rates of Competitors 
7.5.2.1 What Do In-House Counsels Really Cost? 
According to a survey performed in 2006, the national average salaries of 
Canadian in-house counsels were as follows: 
 
Table 7. National Average Salaries for In-House Counsels in Canadian Corporations 
However, it is important to note that the above calculation is misleading because 
it does not take into account all the costs incurred by an employer. As such, one should 
not use the rates showed in Table 7 to compare the costs of in-house counsels with those 
of other providers of legal services. Instead, the real costs of in-house counsels should 
consider all the benefits that the in-house counsels received from their employer. For a 
junior in-house counsel with a base salary of $84,130, this translates into a revised hourly 
Lawyers Low High
Average Mid 
Range Salary
Corresponding 
Hourly Rate
General Counsel 122,470$        223,620$        42,000$          600,000$        173,045$             83.19$                 
Associate General Counsel 102,770$        175,990$        55,000$          400,000$        139,380$             67.01$                 
Senior Lawyer (>5 years) 85,720$          127,450$        53,000$          300,000$        106,585$             51.24$                 
Junior Lawyer (<5 years) 66,620$          101,640$        40,000$          180,000$        84,130$               40.45$                 
[Mid Range]
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rate of $106.19 ($220,869 annually), almost three times as expensive as the base salary. 
Appendix 10: In-House Counsel Real Cost contains the calculation and assumptions used 
to determine the revised hourly rate.   
7.5.2.2 Law Firms’ Overall Costs 
According to a survey performed in 2008 by Kirsten McMahon on behalf of the 
Canadian Lawyer Magazine, the hourly rate of lawyers practising in traditional law firms 
varies between $190 and $360, depending on the location and experience of the lawyer 
(Table 8).  
 2008 Call 2003 Call 1998 Call 
National $220 $310 $310 
1-4 lawyers $220 $275 $280 
5-25 lawyers $220 $350 $360 
26+ lawyers $190 $250 $330 
Ontario $220 $280 $330 
BC $190 $290 $280 
Alberta $210 $290 $260 
Table 8. Hourly Rates Charged by Lawyers Across 
Canada (McMahon, The Going Rate, 2008) 
These rates are also misleading in that the final amount invoiced to a client by a 
law firm includes many other items such as photocopy, long distance telephone calls, 
meals, parking, database searches, etc. These fees are irritating to many clients, but the 
biggest source of dissatisfaction comes from the fact that many different lawyers will bill 
hours on the same matter. Clients do not generally have any control over the number of 
lawyers, students and paralegals involved on their file. There is no doubt that all of these 
people contribute to the file, but it is frequent to see duplication of the same task 
performed by several lawyers, resulting in a hefty final invoice.  
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7.5.3 bio.legal LLP’s Rates 
Although fees are largely market driven, it is commonly suggested to consultants 
to first determine a rate, which, based on assumptions about the capacity, will provide an 
acceptable return on investment and the desired standard of living for the consultants, or 
in bio.legal LLP’s case, the partners (Gray, 2004). In order to determine such rate, 
bio.legal LLP proceeded to a break-even analysis using its amplified annual expenses and 
its final capacity (as defined below). bio.legal LLP used its amplified annual expenses, 
which equal bio.legal LLP’s actual annual expenses in addition to two salaries at average 
market rate, because a break-even analysis using bio.legal LLP’s actual annual expenses 
only would not reflect an acceptable return for bio.legal LLP’s partners. As evidenced in 
Table 9 below, bio.legal LLP could charge between $84.24 and $336.96 per hour 
depending on actual demand, as estimated as a percentage of bio.legal LLP’s final 
capacity.  
 
 
Table 9. Rates to Breakeven 
After having evaluated its competitors’ actual costs, bio.legal LLP has fixed its 
hourly rate at $175, which would more or less guarantee an annual salary of $84,130 plus 
18% statutory and optional benefits to bio.legal LLP’s partners if they work 
Annual Expenses 47,298.44$       
Salary at Average Market Rate 99,273.40$       
Amplified Annual Expenses 245,845.24$     
bio.legal LLP's Final Capacity 2918
Assumptions
Demand (as % 
of capacity)
Corresponding # 
of hours 
Corresponding # 
of days
Rate to 
breakeven
100% 2918.4 365 84.24$                
75% 2188.8 274 112.32$              
50% 1459.2 182 168.48$              
25% 729.6 91 336.96$              
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approximately half of their final capacity. This rate is competitive with the rate charged 
by bio.legal LLP’s most similar competitor, Cognition LLP, which is $200 per hour 
(Appendix 8: Transcript of Interview with Mr. Joe Milestone of Cognition LLP). The 
discrepancy is mostly explained by the location of both firms. 
Discount 
bio.legal LLP will offer a discount of approximately $20 per hour to its clients 
who guarantee at least five complete days of work per month to bio.legal LLP for at least 
three consecutive months. In that case, bio.legal LLP will charge a flat fee of 1,225 per 
day, regardless of the actual number of hours worked.  
Premium 
bio.legal LLP plans on working from the premises of its clients with a direct 
access to administrative resources. If bio.legal LLP’s lawyers have to handle 
administrative tasks, an additional fee of $10 per hour will be charged to the client.  
Pass-thru expenses 
In contrast to law firms, bio.legal LLP will not charge its clients for long distance 
telephone calls, meals, photocopies, parking, etc. Clients will only reimburse bio.legal 
LLP for travel costs incurred at their request. Mileage to and from the clients’ offices will 
not be charged. 
Other Services 
Although it has been estimated that the training sessions would initially take 
approximately 16 hours to prepare, bio.legal LLP will charge a flat rate of $1,600. This 
price is significantly less than what 16 hours would normally cost at bio.legal LLP’s 
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hourly rate because bio.legal LLP desires to use the training session as a way to market 
its services. bio.legal LLP believes that the training sessions will generate questioning 
within the organization and disturb senior management’s complacency.  Furthermore, the 
time required to prepare each presentation will gradually decrease as bio.legal LLP’s 
experience increases. 
No costs have been determined for the establishment of an interactive database or 
for the establishment of a legal department because it is impossible to predict what each 
client will want. The costs of such services will be quoted on a case-by-case basis.  
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8:  MANAGEMENT, ORGANIZATION AND OPERATING 
PLAN 
8.1 Corporate Structure 
This business plan proposes the creation of bio.legal LLP, a limited liability 
partnership (LLP) based out of British Columbia, Canada. bio.legal LLP will be founded 
and managed by Emmanuelle Vallée and Jennifer Begg. The limited liability partnership 
was chosen because it allows for a better tax treatment than a corporation does and it is 
preferable for liability purposes. Under this business plan, bio.legal LLP will only be 
composed of two partners so the risk factor is not significant. However, it is entirely 
possible that demand will exceed what two persons can address. If that happens, bio.legal 
LLP will have the option to take on additional partners or hire employees and/or 
independent contractors. Starting with an LLP allows for flexibility in the future and 
eliminates any duplication of registration fees and other start-up expenses that would 
have to be incurred should the type of entity needed to change to accommodate growth.  
8.2 The Founding Partners 
The founding partners will each have a 50% interest in the partnership.  
8.2.1 Emmanuelle Vallée 
Emmanuelle Vallée graduated from law school in 2004, after having spent one 
third of the program in Belgium where she studied international commercial law. 
Emmanuelle articled and practised law in Montreal at McMillan Binch Mendelsohn with 
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a special focus on corporate/commercial law. Emmanuelle moved to Vancouver to 
undertake a full time Master in Business Administration (MBA) with a special focus in 
Biotechnology offered at Simon Fraser University. Following her MBA, Emmanuelle 
joined Cardiome Pharma Corp. as the Legal Affairs Associate. 
8.2.2 Jennifer Begg 
Jennifer Begg graduated with a Bachelor of Science (Major: Biology and Minor: 
Environmental Toxicology) from Simon Fraser University in 1998. She attended the 
University of British Columbia for her law degree, graduating in 2001. Jennifer spent a 
few years articling and practicing in downtown Vancouver. She joined Cardiome Pharma 
Corp. in 2003, establishing their in-house legal department. 
8.3 Business Location and Size 
bio.legal LLP will not have any business office. Its partners will work either at 
home or directly at their client’s premises.   
8.4 Staff and Equipment Needed 
bio.legal LLP does not expect to hire any administrative staff in its first years of 
existence. Instead, bio.legal LLP will hire New Look Business Centre, a Vancouver-
based company that offers virtual office services. New Look Business Centre will answer 
telephone calls in bio.legal LLP’s name and will receive bio.legal LLP’s couriers and 
mail. If necessary, bio.legal LLP will also have access to New Look Business Centre’s 
facilities such as boardrooms for meetings with clients.  
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A complete list of the equipment required is listed in Appendix 11: List of 
Equipment Required Per Partner.  
8.5 Timeline 
bio.legal LLP plans on formally forming by December 2008 but will initiate 
certain activities earlier in 2008. The first year’s activities will consist primarily of 
advertising and marketing bio.legal LLP’s services, establishing relationships with 
private law firms and building a strong client base. Services could be provided as soon as 
January 2009. An expanded timeline, including all the legal requirements that bio.legal 
LLP needs to comply with, is provided in Appendix 12: Implementation Timeline. 
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9:  FINANCIAL PLAN 
9.1 Underlying Assumptions 
All financial assumptions that were used to arrive at the operating expenses and 
other related costs have been explained in full in Appendix 13: Financial Assumptions. 
When possible, all costs were taken at the going rate announced for 2009 for the region. 
Other costs were taken at the going rate in 2008 for the region or estimated to the best of 
our knowledge.  
9.2 Financial Highlights 
 
Table 10. Summary of Financial Highlights 
A summary of financial highlights is provided above with the accompanying 
financial statements provided in Appendix 14: Financial Projections. Pre-revenues costs 
will be incurred upon formation of the partnership in December 2008 and subsequently 
generate a negative income for that period. Through its second month of existence (first 
month of activity), bio.legal LLP’s net income will become positive and continue to grow 
over $500,000 in 2011. Enough liquidity will be acquired to remain cash flow positive. 
The initial investment will be used to register the partnership, purchase marketing and 
advertising supplies, purchase furniture and equipment, pay for professional and business 
Financial Highlights 2008 2009 2010 2011
Total Revenue 0 275,592 417,131 505,613
EBIT -3,891 234,419 373,806 460,007
Net Profit -3,891 233,602 373,168 459,550
Free Cash Flow 15,569 24,171 53,106 54,300
  
 46 
memberships and for the ongoing expenses incurred during the first two months of 
activity (before revenues from sales are received).  
9.3 Key Financial Indicators 
An overview of financial indicators is provided in Figure 5.  
 
Figure 5. Summary of Key Financial Indicators 2008-2013 
9.4 Breakeven Analysis 
Based upon projected sales, bio.legal LLP is expected to breakeven by mid-April 
2009, which is less than four months after bio.legal LLP will have started its services. At 
that time, bio.legal LLP will have worked more than 270 hours (Figure 6). The breakeven 
point will represent $47,298.44 in sales. This amount is very low because bio.legal LLP, 
as a partnership providing services, has no Cost of Goods Sold, which significantly 
decreases the costs associated with the business operations.  
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Figure 6. bio.legal LLP's Breakeven Point – 270.28 hours 
The breakeven analysis should be used carefully. This business plan will only 
make sense if the partners received appropriate drawings in the absence of a fixed salary.  
9.5 Funding Requirements 
The financing for bio.legal LLP’s venture will be secured through several sources. 
Emmanuelle Vallée and Jennifer Begg will provide personal seed money in the amount 
of $5,000 each.  bio.legal LLP will obtain a bank loan for the remaining $18,000 required 
to fund the initial expenses. It was assumed that bio.legal LLP would be able to secure 
the loan with an interest rate at no more than 5% (prime plus 1%). The credit will be 
issued in mid-December 2008, to minimize the total accrued interest while there is no 
revenue.  
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Table 11. Invested Capital Sources 
 
9.6 Partner’s Drawings 
According to bio.legal LLP’s projections, its partners would be able to receive 
drawings in the amounts described in Table 12 below. These amounts will be divided 
equally amongst Emmanuelle Vallée and Jennifer Begg. 
 
Table 12. bio.legal LLP's Partners' Annual Drawings 
Sources of Funds Amount
Emmanuelle Vallée, Partner $5,000.00
Jennifer Begg, Partner $5,000.00
Long Term Bank Loan $18,000.00
TOTAL $28,000.00
2008 2009 2010 2011
$0 $140,000 $340,000 $440,000
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10:  RISKS 
10.1 Risks 
Although this proposed venture opportunity for bio.legal LLP appears to offer 
profitable outcomes to bio.legal LLP and its partners, it is important to lastly note the 
potential risks inherent to the project. The primary risks have been split into three 
different categories: (1) Competition Reaction, (2) External Factors and (3) Internal 
Factors.  
10.1.1 Competitors’ Reaction 
bio.legal LLP does not expect the traditional law firms to react adversely to 
bio.legal LLP’s entry into the market. It is obvious that bio.legal LLP does not intend to 
replace the traditional law firm’s services for the work outside of their clients’ day-to-day 
operations. Instead, it is expected that bio.legal LLP and the traditional law firms will 
develop mutually beneficial relationships allowing the law firms to allocate their 
resources where needed and leave the low margin legal work to bio.legal LLP.  
bio.legal LLP expects that its services could generate some resistance from 
existing in-house counsels of bio.legal LLP’s clients. Such resistance could be an 
obstacle to the efficient delivery of bio.legal LLP’s services. 
10.1.2 Critical External Factors 
New Entrants: The recent attention given to bio.legal LLP-like companies already on 
the market could lead to a surge of legal services providers using the same business 
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model. bio.legal LLP could face rivalry from those new entrants and have more difficulty 
in establishing and retaining its market share.  
Low demand: In this feasibility report, demand estimates exceed bio.legal LLP’s 
capacity. However, it is possible that demand will turn out to be significantly lower than 
expected therefore affecting the willingness of bio.legal LLP’s partners to continue with 
this venture. 
Recession: A prolonged economic downturn could negatively affect bio.legal LLP’s 
ability to secure work. 
Nature of Biotech/Pharma industry: The Biotech/Pharma industry is highly unstable. 
Mergers, acquisitions, and cessation of activities are frequent outcomes for small to 
medium biotechnology companies. Even if bio.legal LLP is successful in obtaining long-
term commitments from its clients, there is no guarantee that their businesses will remain 
intact through the term of their agreements with bio.legal LLP. 
Client’s decision to hire full time in-house counsel: At one point, bio.legal LLP’s 
clients might decide that they should hire a full time in-house counsel instead of using 
bio.legal LLP’s services. Although bio.legal LLP will attempt to retain some work from 
those clients, it is likely that the hiring of a full time in-house counsel by one client will 
significantly diminish that client’s need for bio.legal LLP’s services. 
10.1.3 Critical Internal Factors 
Ability to respond to demand:  If demand for bio.legal LLP’s services turns out to be as 
estimated, bio.legal LLP will have to grow significantly. bio.legal LLP’s ability to find 
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qualified lawyers and to manage growth is likely to affect bio.legal LLP’s ability to 
service its existing clients.  
Coverage for partners: With only two partners, bio.legal LLP is exposed to coverage 
problems during maternity leave, vacation and sick leave. 
10.1.4 Dealing with Risks 
All of the above-mentioned risks could potentially affect bio.legal’s bottom line. 
bio.legal LLP will remain open minded about servicing early stage companies outside of 
the Biotech/Pharma industry. By enlarging its potential client pool, bio.legal LLP will 
have more chance to secure work and will have access to more qualified lawyers for 
growth.  
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11:  CONCLUSION 
bio.legal LLP’s implementation plan further confirms that a new venture based on 
the model described in this business report would be viable and successful. It is estimated 
that bio.legal LLP will be a profitable business early on in its existence, breaking-even in 
the fourth month following its inception. bio.legal LLP will offer extremely competitive 
rates to its clients and drawings to its partners much higher than the national average mid 
range salaries of in-house legal counsels (Table 7), respectively facilitating the adoption 
of its services and recruitment of talented lawyers if demand turns out to be as estimated.    
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APPENDIX 1: SURVEY TO POTENTIAL CLIENTS 
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APPENDIX 2: SURVEY ANSWERS 
  Respondent #1 Respondent #2 Respondent #3 Respondent #4 Respondent #5 Respondent #6 
How many employees do you 
have? 
2 5 17 < 10 7 
between 10 and 
50 
What were your revenues in 
2007? 
 $ -     $ -     $ -     $ -   $ -   $1 – 10 million 
What are your expected 
revenues for 2008? 
 $ 800,000   $ -     $ -     $ -   $ -     $1 – 10 million 
How many patents do you hold? 
How many patents you have filed 
for? 
8 1 Patent pending 6 
Over 30, 2 
applications 
2 and 27 
How many products do you have 
under development? 
2 1  2 3  
How many products do you have 
on the market? 
1 0 1 0 0 between 1 and 10 
Are you a public company? No No No No Yes Yes 
If you answered yes to the 
previous question, what is your 
market cap? 
n/a n/a n/a n/a $7 million  $50 - 100 million 
What was your R&D 
expenditure on external vendors 
for 2007? 
 $650,000   $50,000   $700,000   $ -  
Approx $3 
million 
 $12,000,000  
What is your expected R&D 
expenditure on external vendors 
for 2008? 
 $150,000   $100,000   $1,500,000   $100,000  
Approx $2.5 
million 
 $5,000,000  
Do you have an in-house legal 
department? 
No No No No No No 
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  Respondent #1 Respondent #2 Respondent #3 Respondent #4 Respondent #5 Respondent #6 
If  you answered no to Question 
#1, who negotiates your day-to-
day contracts? (Please refer to 
the position title) 
CEO 
Fasken Martineau 
DuMoulin LLP 
VP Corporate 
Development 
CEO 
Chief Financial 
Officer, Chief 
Executive Officer 
[Question not 
asked] 
On a scale of one to five, how 
would you say that the strength 
of your day-to-day contracts 
impact the success of your 
company? 
5 - Very 
important. We 
extensively 
negotiate each 
contract 
depending on the 
circumstances. 
5 - Very 
important. We 
extensively 
negotiate each 
contract 
depending on the 
circumstances. 
5 - Very 
important. We 
extensively 
negotiate each 
contract 
depending on the 
circumstances. 
5 - Very 
important. We 
extensively 
negotiate each 
contract 
depending on the 
circumstances. 
5 - Very 
important. We 
extensively 
negotiate each 
contract 
depending on the 
circumstances. 
[Question not 
asked] 
Please briefly explain your 
choice. 
IP and all other 
critical business 
issues flow from 
the contracts with 
contractors 
suppliers etc 
Provide good 
service 
  
Usually start with 
template but 
terms of deal 
require 
negotiation. Also 
important to have 
a comprehensive 
contract. 
Contracts and 
Agreements are 
critical to the 
success of our 
operation. 
[Question not 
asked] 
If you answered no to Question 
#1, please comment briefly why 
you do not have an in-house legal 
department. 
Too expensive Financial reasons   Cost 
Our company is 
too small to 
accommodate in 
house legal. 
Expense 
If you answered no to Questions 
#1, do you expect to establish 
your legal department in the 
near future? When? 
No After 2-3 years No No No No - never 
On average, how much do you 
spend annually on external legal 
fees? 
 $ 60,000.00   $ 20,000.00   $ 150,000.00  $50K-$100K Approx $100,000  $ 250,000.00  
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  Respondent #1 Respondent #2 Respondent #3 Respondent #4 Respondent #5 Respondent #6 
What are the services that you 
receive from your external legal 
counsel? 
            
1. Corporate/ commercial       
2. Litigation          
3. Real estate            
4. Labour          
5. Securities        
6. Financing       
7. Intellectual Property          
8. Draft and negotiation of day-
to-day contracts 
          
What is your level of satisfaction 
with respect to the services 
provided by your external legal 
counsel? 
            
1. Availability Satisfied Highly satisfied 
Highly 
dissatisfied 
Highly satisfied Highly satisfied Satisfied 
2. Cost 
Highly 
dissatisfied 
  Satisfied Dissatisfied Neutral Dissatisfied 
3. Expertise Satisfied   
Highly 
dissatisfied 
Highly satisfied Highly satisfied Highly satisfied 
4. Knowledge of your industry Satisfied   
Highly 
dissatisfied 
Satisfied Highly satisfied Satisfied 
5. Services provided in line with 
you company's strategy 
Highly 
dissatisfied 
  
Highly 
dissatisfied 
Satisfied Highly satisfied Satisfied 
6. Ability to anticipate your 
needs 
Highly 
dissatisfied 
  Satisfied Satisfied Satisfied Dissatisfied 
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  Respondent #1 Respondent #2 Respondent #3 Respondent #4 Respondent #5 Respondent #6 
What do you dislike the most 
about your external legal 
services provider? 
Their fees are 
excessive and 
based on a 
strategy to 
maximize fees not 
for the ultimate 
long term benefit 
of the company 
    Cost Cost Cost 
What do you like the most about 
your external legal services 
provider? 
Quick to respond Prompt services 
Breadth of 
experience in our 
field 
Expertise 
The 
comprehensive 
level of services 
Expertise 
Would you be interested in 
bio.legal LLP's services:  
            
1. On a project basis           
2. On a part time basis?         
3. To cover for maternity or sick 
leave 
            
4. To manage you outside legal 
counsel 
           
If you answered yes to at least 
one of the sub-questions in 
Question #1, how many 
hours/day per week/month do 
you think you would require 
bio.legal LLP's services?  
4 
[bio.legal LLP 
assumed 4 
days/month] 
0 0 1 day a month 
[Question not 
answered] 
20 hrs / mo 
[bio.legal LLP 
assumed 3 
days/month] 
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  Respondent #1 Respondent #2 Respondent #3 Respondent #4 Respondent #5 Respondent #6 
If you answered yes to at least 
one of the sub-questions in 
Question #1, which services 
would interest you the most (you 
can select more than one 
answer)? 
            
1. Negotiation of day-to-day 
contracts  
          
2. Human resources support            
3. Securities/financing           
4. Litigation           
5. Major agreements           
6. Management of Intellectual 
Property Portfolio 
          
Would you be interested in 
bio.legal LLP's services to (you 
can select more than one 
answer): 
            
1. Train your employees on the 
importance of basic legal 
concepts 
          
 
2. Establish your legal 
department  
           
3. Establish a central interactive 
database for the request, 
review and storage of your 
contracts 
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  Respondent #1 Respondent #2 Respondent #3 Respondent #4 Respondent #5 Respondent #6 
If you answered no to all the sub-
questions in Question #1, please 
explain why you would not be 
interested in bio.legal LLP's 
services? 
  
We have an 
ongoing contract 
with Fasken 
Martineau 
DuMoulin LLP at 
this time 
We are very 
pleased with the 
services we 
receive today 
from our law 
firms. 
      
Please add any other comments 
you may have.  
Bio legal is a very 
good idea and my 
company would 
support it - only if 
the lawyers in the 
group comprise 
experts in the 
fields of law 
needed for the bio 
tech company 
        
Don’t really 
understand what 
the difference is 
between 
bio.legal's 
services and 
retaining a 
regular, full-
service law firm 
on a time and 
materials basis.  
The full service 
firm has a variety 
of lawyers, can 
act as a team, 
provides the same 
cost-benefit re 
lack of overhead 
of inside counsel, 
and etc. - need to 
differentiate the 
concept better for 
me to buy into it. 
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APPENDIX 3: LIST OF BIOTECH/PHARMA COMPANIES 
 
Adnavance Technologies Inc.   Migenix Inc.   
Allon Therapeutics Inc.   MIV Therapeutics Inc.   
Angiotech Pharmaceuticals, Inc.   Neuromed Pharmaceuticals   
ARC Pharmaceuticals   Novation Pharmaceuticals   
Augurex Life Sciences Corp.   Ondine Biopharma Corporation   
Biotech Holdings   Pacgen Biopharmaceuticals Corporation   
Cardiome Pharma Corp.   Pacific Therapeutics Ltd.   
Celator Pharmaceuticals Corp.   Panagin Pharmaceuticals Inc   
Centre for Drug Research and Development   Pegasus Pharmaceuticals Group Inc.   
Chemokine   Therapeutics Corp.   Perceptronix   
Chromos Molecular Systems Inc.   Pharmanutrients Botanical Corporation   
Clinotech Diagnostics & Pharmaceuticals Inc   Protox Therapeutics Inc.   
Eastwood Bio - Medical Research Inc.   Pyng Medical Corp.   
enGene Inc.   QLT Inc.   
Forbes Medi - Tech Inc.   Response Biomedical Corp.   
Heart Force Medical   Sirius Genomics Inc.   
iCell Therapeutics   Tekmira Pharmaceuticals Corporation   
iCo Therapeutics Inc.   Twinstrand Therapeutics Inc.   
IND Lifetech Inc.   WEX Pharmaceuticals Inc.   
Indel   Therapeutics Inc.   Xenon Pharmaceuticals Inc.   
Inflazyme Pharmaceuticals Ltd.   Zecotek Medical Systems Inc.   
Inimex Pharmaceuticals, Inc.   Urodynamix Technologies Ltd.   
Link Core Pharma Limited   Vancouver Biotech Ltd.   
Med BioGene   Vifor Aspreva   
Medical Ventu res Corp.   ViroForce Systems Inc.   
Microbion BioSciences Corporation   Welichem Biotech Inc.   
Microtek International Inc.     
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APPENDIX 4: DEMAND ESTIMATES ASSUMPTIONS 
Demand Estimates for bio.legal LLP’s services depends on two different factors 
external to bio.legal LLP’s: (1) the number of potential clients and (2) the anticipated 
individual need. 
1. The Number of Potential Clients 
The number of potential clients was taken from three different sources: 
 BC Ministry of Development: 154 Biotech/Pharna Companies (91 
biopharmaceuticals and 63 medical devices 
 
 Life Sciences British Columbia: more than 90 Biotech/Pharma Companies 
 
 List put together by bio.legal LLP: 53 Biotech/Pharma Companies 
 
2. The Anticipated Individual Need 
According to the responses to bio.legal LLP’s survey, three (3) companies out of six (6) 
would required eight (8) days of work per month from bio.legal LLP, which translate into 
an average of 1.33 day per month per company. A fourth respondent said it would use 
bio.legal LLP’s services but did not specify how many hours per month it would require. 
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APPENDIX 5: SALES FORECAST ASSUMPTIONS 
It is estimated that a trial implementation of bio.legal LLP’s services in one 
Biotech/Pharma Company will lead to a stronger adoption of bio.legal LLP’s services 
within that company. According to Mr. Joe Milestone, clients rapidly increase the 
number of hours they require from Cognition LLP once they realized that Cognition 
LLP’s services actually added value to their businesses at a very low cost (Milstone, 
2008). Furthermore, we anticipate that word of mouth will lead to greater adoption 
throughout the biotech/pharma industry in British Columbia. These two assumptions 
have been depicted in Table 13. Monthly Sales Forecast for bio.legal LLP's First Three 
Years, which displays bio.legal LLP’s predicted sales from inception (2009) to 2011.  
 
Table 13. Monthly Sales Forecast for bio.legal LLP's First Three Years 
Month % Hours Value Month % Hours Value Month % Hours Value
Jan 20% 57.60 10,080.00$    Jan 66% 190.08 33,264.00$    Jan 80% 230.40 40,320.00$    
Feb 24% 73.51 12,864.73$    Feb 66% 200.64 35,112.00$    Feb 80% 243.20 42,560.00$    
Mar 28% 99.84 17,472.00$    Mar 66% 232.32 40,656.00$    Mar 80% 281.60 49,280.00$    
April 33% 83.32 14,580.36$    April 66% 168.96 29,568.00$    April 80% 204.80 35,840.00$    
May 37% 88.15 15,425.45$    May 66% 158.40 27,720.00$    May 80% 192.00 33,600.00$    
June 41% 144.00 25,200.00$    June 66% 232.32 40,656.00$    June 80% 281.60 49,280.00$    
July 45% 122.65 21,463.27$    July 66% 179.52 31,416.00$    July 80% 217.60 38,080.00$    
Aug 49% 118.25 20,694.55$    Aug 66% 158.40 27,720.00$    Aug 80% 192.00 33,600.00$    
Sept 53% 179.61 31,431.27$    Sept 66% 221.76 38,808.00$    Sept 80% 268.80 47,040.00$    
Oct 58% 193.66 33,890.18$    Oct 66% 221.76 38,808.00$    Oct 80% 268.80 47,040.00$    
Nov 62% 197.82 34,618.18$    Nov 66% 211.20 36,960.00$    Nov 80% 256.00 44,800.00$    
Dec 66% 232.32 40,656.00$    Dec 66% 232.32 40,656.00$    Dec 80% 281.60 49,280.00$    
Total 1590.72 278,376.00$  Total 2407.68 421,344.00$  Total 2918.40 510,720.00$  
20102009 2011
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APPENDIX 6: CALENDAR OF PROFESSIONAL 
DEVELOPMENT 
The Law Society of British Columbia requires its members to attend at least 12 
hours of continuing legal education annually. The table below displays a calendar of 
professional development activities that comply with the BC Law Society’s requirements 
and that are extremely relevant to bio.legal LLP’s area of expertise. The Life Sciences 
Industry Roundtables were included to ensure that bio.legal LLP would provide legal and 
business advices in line with the biotechnology industry’s most recent standards.  
 
It was assumed that both partners would attend the same conferences. 
 
Conference Title
Dates of 
Conference
Location
# of days  
(with 
travel)
Due Date 
(Early Bird 
Payment)
Month 
Expense 
Incurred
 Cost 
Corporate Counsel: Regulatory Advisor, 
Compliance Officer, Governance Gatekeeper
Apr 5-7, 2009 Mtl 5 06-Mar-09 Mar-09 1,213$   
CCCA's 2009 Corporate Counsel World Summit Jan 26-27, 2009 Van 2 20-Nov-08 Jan-09 893$      
Legal Strategies For Business Acquisitions 2009 13-Feb-09 Van 1 16-Jan-09 Jan-09 445$      
Solo and Small Firm Conference 2009 22-Jan-09 Van 1 22-Dec-08 Jan-09 495$      
Life Sciences Industry Roundtable 3 per year Van n/a n/a
Apr-09                    
Aug-09                      
Nov-09
75$
CD Only: Negotiating Clinical Trial Agreements n/a n/a n/a n/a Jun-09 349$      
9 Total 3,469$   
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APPENDIX 7: BIO.LEGAL LLP’S WORKING DAYS IN 
2009 
 
 
 
 
 
 
Week days 22 Week days 20 Week days 22 Week days 22
Statutory holidays 1 Statutory holidays 0 Statutory holidays 0 Statutory holidays 1
Vacation 0 Vacation 0 Vacation 0 Vacation 0
Conferences 3 Conferences 1 Conferences 0 Conferences/Travel 5
Working days 18 Working days 19 Working days 22 Working days 16
Week days 21 Week days 22 Week days 23 Week days 21
Statutory holidays 1 Statutory holidays 0 Statutory holidays 1 Statutory holidays 1
Vacation 5 Vacation 0 Vacation 5 Vacation 5
Conferences/Travel 0 Conferences/Travel 0 Conferences 0 Conferences 0
Working days 15 Working days 22 Working days 17 Working days 15
Week days 22 Week days 22 Week days 21 Week days 23
Statutory holidays 1 Statutory holidays 1 Statutory holidays 1 Statutory holidays 1
Vacation 0 Vacation 0 Vacation 0 Vacation 0
Conferences 0 Conferences 0 Conferences 0 Conferences 0
Working days 21 Working days 21 Working days 20 Working days 22
February 2009
August 2009
March 2009
September 2009
April 2009
Octobre 2009
Janvier 2009
May 2009
November 2009
June 2009
December 2009
July 2009
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APPENDIX 8: TRANSCRIPT OF INTERVIEW WITH MR. 
JOE MILESTONE OF COGNITION LLP 
Demographic questions 
1. Do your clients come from one specific industry? 
Mostly information technology and telecommunication but also from other industries 
 
2. What size/kind of company do you serve?  
1) Companies that don’t have in-house counsel 
2) Supplementary to existing in-house department 
 
3. What geographic area do you serve?  
Toronto, Ottawa, Waterloo, Kitchener. Have tried to expand to Calgary, but it did not work. Are now 
looking to expand in Vancouver 
 
4. How many employees do you have? 
15 to 20 lawyers 
 
5. When did you start your consulting business? 
Business model was created about 5 years ago. Cognition was founded in April, 2005. 
Start-up – Growth 
6. How long did it take before your business became profitable? 
Business was profitable almost right away due to very low overhead (next to nothing) 
 
7. How fast did you grow?  
From 2 to 20 lawyers in 5 years. Not all lawyers have full time assignment, but most of them do.  
 
8. Where you do see your company in one (1) year? Five (5) years? 
Want to grow geographically. Use Axiom as model.  
Competition 
9. Have you encountered any resistance from employees of your clients while performing your 
services? Do you think that you would have encountered the same resistance if you had been an 
employee and not a consultant?  
Not too much – they don’t see resistance as a problem. 
When they go in, they have the endorsement of the CEO and CFO.  
Their lawyers all have previous experience as in-house counsel. They know how to manage transition 
and changes. 
 
10. Have you noticed any adverse reaction from the traditional law firms since you have started 
your business?  
In most cases, Cognition LLP does not show on law firms’ radar screen. 
 
Sometimes, they get placed by law firms. They don’t do the big transactions, so forward looking law 
firms know that they won’t lose the client. 
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Cognition LLP is taking a certain amount of market share from law firms, but client’s satisfaction 
ultimately prevails. Thus, the problem remains only until the law firms realize that they will keep 
enough business. 
 
11. Are you aware of any direct competitors offering the same kind of services in Ontario? In 
Canada? 
In Canada, there is Delegatus but it is more like a small law firm than a corporation based on the new 
business model. 
In the USA, Axiom is a great model of how successful this business can be.  
Marketing 
12. What has been the best way to market your services? 
Grab someone’s attention for 5 minutes.  
Meet people. 
Word of mouth from existing clients. 
Setup a booth at different shows and attend every show designed for in-house counsels 
 
13. On average, what is your annual marketing budget? 
Approximately $50,000 this year – shows, travel, materials 
Services and rates 
14. What are your rates on average? 
Same rate for each lawyer - if there is any discrepancy; it is linked to the type of services 
(corporate/financing or highly specialized) 
Hourly: $200 
Daily (for any commitment of 1 ½ days and up per week): $1,300-$1,400 
Corporate transactions/Specialized work: $250 
They do not charge travel time to go to clients, nor long distances, photocopies or faxes 
 
15. On average, how many hours per week/month does one client require? Have you identified any 
factor(s) (e.g. revenues, number of products on the market, number of employees, etc.) that 
directly influence the number of hours that one client requires? 
There is no factor that allows determining how many hours a client will require. It is different for each 
client. Usually, clients start with a small number and then go up over time when they realize the value 
added and the low cost.  
 
16. Do you train other people (executive, contracts manager, and articling students) to do your job 
at your client? Within your own business?  
Lawyers come fully trained. The most important qualification is past experience as in-house counsel. 
 
17. Do you charge the training cost to your clients? 
There is no overlap, and this is something that Cognition LLP clients appreciate compared to law 
firms.  
 
18. Do you know if your clients have completely stopped using private law firms after you started 
working with them? 
No, they don’t. (see reaction from law firms) 
Finance and Organization 
19. On average, what are you annual expenses? What are the largest items of your expenses? 
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Very low expenses. They got an office about 1 ½ year ago outside of the main core in Toronto. It’s a 
small office with 4-5 desks that they share with an architect. They use the office to store files and 
meet.  They also hired an administrative assistant 5 to 6 months ago. Cost is negligible, less than 
$1,000/month.  
 
20. How much of your time do you spend managing your business and employees compare to 
working billable hours for clients? 
When they started, both partners mostly work on billable hours with not much time spent on 
marketing. Now, they spend about half of their time on assignment and the other half on marketing 
Cognition LLP and developing new markets. Soon, they will spend most of their time on marketing. 
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APPENDIX 9: TRANSCRIPT OF INTERVIEW WITH SAGE 
BAKER OF FD INTERNATIONAL 
21. What does it take to succeed as a consultant?  
 
 Ensuring clients’ needs are put first. Billing and profits should not be a priority. If you are doing 
a good job at servicing your clients properly, profitability will come with it. 
 Be proactive and bring value to your clients’ businesses. 
 
22. Based on your experience, what are the most important factors that influence one’s decision to 
hire a consultant?  
 
 Prior experience is a key determiner. Clients need to know that you have the ability 
(qualifications) to take care of their needs. 
 Physical location 
 Pricing 
 
Marketing 
23. What has been the best way to market your services? 
 
 Target clients that have been identified as needing consultant’s services. This research is made 
through public releases, industry profiles, market research, etc. 
 Met with executives with a plan to address existing needs. 
 Website is good, but clients usually look at website after a first interaction with the consultant. 
 
Competition 
24. When you are (were) consulting, are (were) you in direct competition with full time employees? 
How do you differentiate yourself? 
 
Yes. Differentiate by bringing more to business. 
 
25. Have you encountered any resistance from employees of your clients while performing your 
services? Do you think that you would have encountered the same resistance if you had been an 
employee and not a consultant? How do you overcome the resistance? 
 
Yes. You should aid and assist those employees and build a relationship with them. They need to need 
you as much as the company does. Don’t go to the CEO and use the CEO card when there’s tension. 
The CEO needs to buy in, but the “resistant” employees also need to see you as a collaborator.  
 
26. FD International is comparable to a large law firm in that it offers a wide range of services, has 
offices around the world and has many employees. Do you consider smaller consulting 
boutiques competition? Would you collaborate with them for smaller matters?  
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FD International and smaller consulting boutiques do not have the same clients. FD is too expensive 
for smaller clients. FD sometimes passes smaller files to boutiques when they know that the file will 
not be profitable. Smaller boutiques will sometime claim that they can manage big files. FD believes 
that smaller boutiques cannot offer good services to large clients because they don’t have enough 
resources. 
 
Services 
27. Do you train other people to do your job with your client? Within your own business? 
 
Both. Always looking at future relationships. In the long term, it makes more sense from business 
point of view to train people from the consulting organization. However, they have helped clients to 
set-up full time employees or department, but only because they knew that they would retain some 
business from it. Always kept long term needs in mind and they will only do it if it makes sense and if 
future business will come out of that. 
 
28. Do you charge the training costs to your clients? No. FD assumes as cost of doing business. 
 
Finance and Organization 
29. How much of your time do you spend managing your business and employees compared to 
working billable hours for clients? 
 
1/3 business development - 1/3 office management - 1/3 clients. In the future, when her market will be 
more developed, will spend 70% on clients. 
 
30. When you left Aspreva, did you consider starting another consulting business? If yes, why did 
you choose to work with FD International?  
 
Yes she did, but looking and anticipating shift in economy, she preferred the stability of being an 
employee. 
 
Other thoughts 
- Should find ways to work with larger law firms – mutually beneficial relationship 
- Good niche to play in but revenues stream is uncertain. 
- Expand target clients to all early-stage companies. Biotech in BC is a small market. Diversifying 
services to early-stage companies of other industries would allow for more revenues. 
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APPENDIX 10: IN-HOUSE COUNSEL REAL COST 
 
 
  
 82 
Assumptions: 
1. Base Salary and Stock Options value were taken from the Canadian Lawyer 
Magazine's annual corporate counsel survey (McMahon, Annual Corporate 
Counsel Survey, 2006); 
2. Annual Bonus of $22,290 according to McMahon was reduced to $5,000 because 
evaluated to be more accurate; 
3. Value of office space was omitted because bio.legal LLP is likely to work on site 
as well; 
4. Costs of parking, professional membership, computer, Blackberry/Cell phone and 
professional development were included because bio.legal LLP assume these 
costs for its partners without any charge back to clients; 
5. Hiring costs were omitted because similar costs will be incurred in selecting 
bio.legal LLP; and 
6. Severance package was averaged to two months of base salary. 
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APPENDIX 11: LIST OF EQUIPMENT REQUIRED PER 
PARTNER 
 
 
Furniture Computer & Equipment
Bow-Front Desk Laptop
Right-Hand Corner Desk External Hard Drive
Hutch USB Key
Lateral File Printer all in one
Chair Motorola Headset
Garbage Shredder
Dry Erase Board Blackberry
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APPENDIX 12: IMPLEMENTATION TIMELINE 
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APPENDIX 13: FINANCIAL ASSUMPTIONS 
Accounts Receivable 
Consulting fees will be invoiced monthly and accounts will be 30 days net. For the 
purpose of cash flow projection, monthly sales (consulting service fees) will be recorded 
as revenues one month after invoice has been issued (e.g. work performed in March, 
invoice issued in April, revenues recorded in May).  This means that for any given 
period, bio.legal LLP will carry forward the last two months of such period. 
Accounts Payable 
No accounts payable will be carried forward. 
Bad Debt 
bio.legal LLP has attributed one per cent (1%) of the total revenues to bad debt and 
deducted such amount from the revenues.  
Bank charges, Loan Repayment and Interests 
Bank charges are anticipated to be the same amount each month and paid for in the 
month the expense is incurred. Principal amount payable on loan is the same each month 
($300 starting in January 2009). Interest will be paid monthly in accordance with the 
schedule in Table 14 below.  
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Table 14. Monthly Interest Payment 
bio.legal LLP’s Rates 
It was assumed that there would be no increase in bio.legal LLP’s rates over the first 
three years.  
Capacity 
bio.legal LLP’s capacity is 2,918 hours per year or 1,459 hours per partner. 
Capital Expenditures 
 
Table 15. Capital Expenditures 
Capital expenditures on furniture, computers and equipment are required to start 
providing the services. The furniture, computers and equipment have a useful life of 5 
years. 
2008 2009 2010 2011 2012 2013
Jan -$         75.00$          60.00$            45.00$            30.00$            15.00$            
Feb -$         73.75$          58.75$            43.75$            28.75$            13.75$            
March -$         72.50$          57.50$            42.50$            27.50$            12.50$            
April -$         71.25$          56.25$            41.25$            26.25$            11.25$            
May -$         70.00$          55.00$            40.00$            25.00$            10.00$            
June -$         68.75$          53.75$            38.75$            23.75$            8.75$               
July -$         67.50$          52.50$            37.50$            22.50$            7.50$               
Aug -$         66.25$          51.25$            36.25$            21.25$            6.25$               
Sept -$         65.00$          50.00$            35.00$            20.00$            500.00$          
Oct -$         63.75$          48.75$            33.75$            18.75$            3.75$               
Nov -$         62.50$          47.50$            32.50$            17.50$            2.50$               
Dec -$         61.25$          46.25$            31.25$            16.25$            1.25$               
-$         817.50$        637.50$          457.50$          277.50$          592.50$          
Furniture, Computer & Equipment
Furniture 4,778.97$       
Computers 1,469.98$       
Other Electronic Equipment 2,291.48$       
Total: 8,540.42$       
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Continuing Legal Education 
Conferences fees have been calculated using the early bird fees and incurred in the period 
during which the early bird fee is available. It was assumed that both partners would 
attend the conferences listed in Appendix 6: Calendar of Professional Development.  
Cost of Goods Sold 
Cost of Goods Sold (COGS) for a service provider is equal to the direct labour required 
to perform the services. Since partners in a partnership like bio.legal LLP are not entitled 
to a fixed salary, there are no COGS in the income statement of bio.legal LLP.  
Depreciation 
Capital assets were depreciated using a straight-line method over the useful life of the 
assets: 5 years for the furniture, the computers and the other electronic equipment.  
Income Tax, PST and GST  
As a partnership, bio.legal LLP is not a taxable entity. The revenues will be split amongst 
the partners and only the partners will pay taxes on their respective portion. bio.legal LLP 
will have to pay GST, but will not carry any GST account forward.  
Inflation 
An inflation rate of 6% was applied to all operating expenses. The inflation rate was not 
applied to bio.legal LLP’s rates. 
Partner Drawings 
As the partners of bio.legal LLP do not get a fixed salary, drawings will be the partners’ 
only source of income. It has been assumed that partners will get drawings every year in 
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substantial amounts payable quarterly starting from the third quarter of 2009. The 
amounts proposed are subject to change and drawings will not be made or will be made 
in smaller amounts if bio.legal LLP does not have enough liquidity to assume its financial 
obligations in subsequent periods.  
Partnership’s financial statements 
bio.legal LLP will prepare income statements that do not include Cost of Goods Sold or 
partners’ salaries as expenses. However, the balance sheets with include equity accounts 
analogous to Paid-In Capital and Retained Earnings.  
Professional Fees 
Start-up and accounting fees will be higher in the “pre-activity” phase. It was assumed 
that the fees of registration of bio.legal LLP would not be included in the accounting fees. 
Once activity begins, professional fees will be paid to an accountant to maintain financial 
records. 
Sales Revenue 
The income is based on the overall sales forecast described in Appendix 5: Sales Forecast 
Assumptions.  
Rent 
bio.legal will not pay rent. Partners will work from their respective homes or directly at 
their client’s premises. 
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APPENDIX 14: FINANCIAL PROJECTIONS 
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PROJECTED BALANCE SHEET
bio.legal LLP
31-Dec-08 31-Dec-09 31-Dec-10 31-Dec-11
ASSETS 31-Mar-09 30-Jun-09 30-Sep-09
Current Assets
Cash in bank 15,569$    3,579$       36,951$    28,020$    24,171$    53,106$    54,300$      
Account Receivable -                30,337       40,625      52,126      75,274      77,616      94,080        
Professional Membership -                7,834         7,834        7,834        7,834        -               -                 
(Less accumulated deprecitation) -                (1,958)       (3,917)       (5,875)      (7,834)      -               -                 
Other 3,891        3,891         3,891        3,891        3,891        3,891        3,891          
Total current assets 19,460$    43,682$     85,384$    85,994$    103,336$  134,612$  152,270$    
Fixed Assets
Equipment 3,761$      3,761$       3,761$      3,761$      3,761$      3,761$      3,761$        
(Less accumulated depreciation) -                (188)          (376)          (564)         (752)         (1,505)      (2,257)        
Furniture & Fixtures 4,779        4,779         4,779        4,779        4,779        4,779        4,779          
(Less accumulated 
deprecreciation) -                (239)          (478)          (717)         (956)         (1,912)      (2,867)        
Other -                -                -                -               -               -               -                 
Total fixed assets 8,540$      8,113$       7,686$      7,259$      6,832$      5,124$      3,416$        
Total assets 28,000$    51,795$     93,070$    93,254$    110,168$  139,737$  155,686$    
LIABILITIES & NET WORTH
Current liabilities
Bank indebtness (line of credit) -$              -$              -$              -$             -$             -$             -$               
Current portion long-term debt 3,600        3,600         3,600        3,600        3,600        3,600        3,600          
Other current liabilities (specify) -                -                -                -               -               -               -                 
Total current liabilities 3,600$      3,600$       3,600$      3,600$      3,600$      3,600$      3,600$        
Long-term liabilities
Bank loans payable (greater than 
12 months) 18,000$    17,100$     16,200$    15,300$    14,400$    10,800$    7,200$        
(Less: Short-term portion) (3,600)       (3,600)       (3,600)       (3,600)      (3,600)      (3,600)      (3,600)        
Total long-term liabilities 14,400$    13,500$     12,600$    11,700$    10,800$    7,200$      3,600$        
Total liabilities 18,000$    17,100$     16,200$    15,300$    14,400$    10,800$    7,200$        
Owners' Equity
Invested capital 10,000$    10,000$     10,000$    10,000$    10,000$    10,000$    10,000$      
Retained earnings - beginning -                -                24,695      66,870      67,954      85,768      118,937      
Retained earnings - current -                24,695       42,175      61,084      97,814      373,168    459,550      
(Less drawings) -                -                (60,000)    (80,000)    (340,000)  (440,000)    
Owners' equity (net worth) 10,000$    34,695$     76,870$    77,954$    95,768$    128,937$  148,486$    
Total liabilities & Net worth 28,000$    51,795$     93,070$    93,254$    110,168$  139,737$  155,686$    
  
 91 
 
P
R
O
J
E
C
T
E
D
 C
A
S
H
 F
L
O
W
b
io
.l
eg
a
l 
L
L
P
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
Q
1
Q
2
Q
3
Q
4
C
a
sh
 a
t 
b
eg
in
n
in
g
 o
f 
a
ct
iv
it
es
C
as
h
 b
al
an
ce
 a
t 
th
e 
b
eg
in
n
in
g
 o
f 
th
e 
p
er
io
d
-
  
  
  
  
  
  
  
  
1
5
,5
6
9
  
  
  
 
3
,5
7
9
  
  
  
  
 
3
6
,9
5
1
  
  
  
 
2
8
,0
2
0
  
  
  
 
1
5
,5
6
9
  
  
  
 
2
4
,1
7
1
  
  
  
 
5
3
,1
0
6
  
  
  
 
C
a
sh
 f
lo
w
s 
fr
o
m
 o
p
er
a
ti
n
g
 a
ct
iv
it
ie
s
N
et
 i
n
co
m
e
(3
,8
9
1
)
  
  
  
 
2
4
,6
9
5
  
  
  
 
4
2
,1
7
5
  
  
  
 
6
1
,0
8
4
  
  
  
 
9
7
,8
1
4
  
  
  
 
2
3
3
,6
0
2
  
  
 
3
7
3
,1
6
8
  
  
 
4
5
9
,5
5
0
  
  
 
D
ep
re
ci
at
io
n
 a
d
d
 b
ac
k
-
  
  
  
  
  
  
  
  
2
,3
8
5
  
  
  
  
 
2
,3
8
5
  
  
  
  
 
2
,3
8
5
  
  
  
  
 
2
,3
8
5
  
  
  
  
 
1
,7
0
8
  
  
  
  
 
1
,7
0
8
  
  
  
  
 
1
,7
0
8
  
  
  
  
 
In
v
en
to
ry
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
A
cc
o
u
n
t 
R
ec
ei
v
ab
le
-
  
  
  
  
  
  
  
  
(3
0
,3
3
7
)
  
  
 
(1
0
,2
8
9
)
  
  
 
(1
1
,5
0
0
)
  
  
 
(2
3
,1
4
8
)
  
  
 
(7
5
,2
7
4
)
  
  
 
(2
,3
4
2
)
  
  
  
 
(1
6
,4
6
4
)
  
  
 
O
th
er
 p
u
rc
h
as
es
-
  
  
  
  
  
  
  
  
(7
,8
3
4
)
  
  
  
 
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
(7
,8
3
4
)
  
  
  
 
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
N
et
 c
as
h
 p
ro
v
id
ed
 (
u
se
d
) 
b
y
 o
p
er
at
in
g
 a
ct
iv
it
ie
s
(3
,8
9
1
)
  
  
  
 
(1
1
,0
9
0
)
  
  
 
3
4
,2
7
2
  
  
  
 
5
1
,9
6
9
  
  
  
 
7
7
,0
5
2
  
  
  
 
1
5
2
,2
0
2
  
  
 
3
7
2
,5
3
5
  
  
 
4
4
4
,7
9
4
  
  
 
C
a
sh
 f
lo
w
s 
fr
o
m
 i
n
v
es
ti
n
g
 a
ct
iv
it
ie
s
C
as
h
 p
ai
d
 f
o
r 
p
u
rc
h
as
e 
o
f 
ca
p
it
al
 a
ss
et
s
(3
,7
6
1
)
  
  
  
 
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
O
th
er
(4
,7
7
9
)
  
  
  
 
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
N
et
 c
as
h
 p
ro
v
id
ed
 (
u
se
d
) 
b
y
 i
n
v
es
ti
n
g
 a
ct
iv
it
ie
s
(8
,5
4
0
)
  
  
  
 
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
C
a
sh
 f
lo
w
s 
fr
o
m
 f
in
a
n
ci
n
g
 a
ct
iv
it
ie
s
C
as
h
 r
ec
ei
v
ed
 f
ro
m
 i
ss
u
in
g
 s
to
ck
1
0
,0
0
0
  
  
  
 
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
C
as
h
 r
ec
ei
v
ed
 f
ro
m
 l
o
n
g
-t
er
m
 b
o
rr
o
w
in
g
s
1
8
,0
0
0
  
  
  
 
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
C
as
h
 p
ai
d
 t
o
 r
et
ir
e 
lo
n
g
-t
er
m
 d
eb
t
-
  
  
  
  
  
  
  
  
(9
0
0
)
  
  
  
  
  
(9
0
0
)
  
  
  
  
  
(9
0
0
)
  
  
  
  
  
(9
0
0
)
  
  
  
  
  
(3
,6
0
0
)
  
  
  
 
(3
,6
0
0
)
  
  
  
 
(3
,6
0
0
)
  
  
  
 
C
as
h
 p
ai
d
 t
o
 d
ra
w
in
g
s
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
-
  
  
  
  
  
  
  
  
(6
0
,0
0
0
)
  
  
 
(8
0
,0
0
0
)
  
  
 
(1
4
0
,0
0
0
)
  
 
(3
4
0
,0
0
0
)
  
 
(4
4
0
,0
0
0
)
  
 
N
et
 c
as
h
 p
ro
v
id
ed
 (
u
se
d
) 
in
 f
in
an
ci
n
g
 a
ct
iv
it
ie
s
2
8
,0
0
0
  
  
  
 
(9
0
0
)
  
  
  
  
  
(9
0
0
)
  
  
  
  
  
(6
0
,9
0
0
)
  
  
 
(8
0
,9
0
0
)
  
  
 
(1
4
3
,6
0
0
)
  
 
(3
4
3
,6
0
0
)
  
 
(4
4
3
,6
0
0
)
  
 
In
cr
e
a
se
 (
d
ec
r
ea
se
) 
in
 c
a
sh
 d
u
ri
n
g
 t
h
e 
p
er
io
d
1
5
,5
6
9
  
  
  
 
(1
1
,9
9
0
)
  
  
 
3
3
,3
7
2
  
  
  
 
(8
,9
3
1
)
  
  
  
 
(3
,8
4
8
)
  
  
  
 
8
,6
0
2
  
  
  
  
 
2
8
,9
3
5
  
  
  
 
1
,1
9
4
  
  
  
  
 
C
a
sh
 b
a
la
n
ce
 a
t 
th
e 
en
d
 o
f 
th
e 
p
er
io
d
1
5
,5
6
9
  
  
  
 
3
,5
7
9
  
  
  
  
 
3
6
,9
5
1
  
  
  
 
2
8
,0
2
0
  
  
  
 
2
4
,1
7
1
  
  
  
 
2
4
,1
7
1
  
  
  
 
5
3
,1
0
6
  
  
  
 
5
4
,3
0
0
  
  
  
 
